214 related articles for article (PubMed ID: 8305784)
1. Atovaquone: a review.
Haile LG; Flaherty JF
Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
[TBL] [Abstract][Full Text] [Related]
2. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
Spencer CM; Goa KL
Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
[TBL] [Abstract][Full Text] [Related]
4. Optimizing PCP therapy.
Torres G; Cadman J
GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
6. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
7. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
8. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Korraa H; Saadeh C
South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
[TBL] [Abstract][Full Text] [Related]
9. Atovaquone: a new antipneumocystis agent.
Artymowicz RJ; James VE
Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
[TBL] [Abstract][Full Text] [Related]
10. Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration.
Cotton D
AIDS Clin Care; 1995 Jul; 7(7):62. PubMed ID: 11362554
[TBL] [Abstract][Full Text] [Related]
11. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
[TBL] [Abstract][Full Text] [Related]
13. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ
Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228
[TBL] [Abstract][Full Text] [Related]
14. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
[TBL] [Abstract][Full Text] [Related]
15. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C; Katergi K; Sorin M; Rjeily MB; Butler-Laporte G; McDonald EG; Lee TC
Clin Microbiol Infect; 2024 Jul; 30(7):866-876. PubMed ID: 38583518
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.
Falloon J; Sargent S; Piscitelli SC; Bechtel C; LaFon SW; Sadler B; Walker RE; Kovacs JA; Polis MA; Davey RT; Lane HC; Masur H
Pharmacotherapy; 1999 Sep; 19(9):1050-6. PubMed ID: 10610011
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.
Meyers B; Borrego F; Papanicolaou G
Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024
[TBL] [Abstract][Full Text] [Related]
20. Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
Zarkin GA; Bala MV; Wood LL; Bennett CL; Simpson K; Dohn MN
Pharmacoeconomics; 1996 Jun; 9(6):525-34. PubMed ID: 10160480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
